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Abstract
Background: Molecular breast imaging (MBI) performed with 99mTc sestamibi has been shown to be a valuable
technique for the detection of breast cancer. Alternative radiotracers such as 99mTc maraciclatide may offer
improved uptake in breast lesions. The purpose of this study was to compare relative performance of 99mTc
sestamibi and 99mTc maraciclatide in patients with suspected breast cancer, using a high-resolution dedicated
gamma camera for MBI. Women with breast lesions suspicious for malignancy were recruited to undergo two MBI
examinations—one with 99mTc sestamibi and one with 99mTc maraciclatide. A radiologist interpreted MBI studies in
a randomized, blinded fashion to assign an assessment score (1–5) and measured lesion size. Lesion-to-background
(L/B) ratio was measured with region-of-interest analysis.
Results: Among 39 analyzable patients, 21 malignant tumors were identified in 21 patients. Eighteen of 21 tumors
(86%) were seen on 99mTc sestamibi MBI and 19 of 21 (90%) were seen on 99mTc maraciclatide MBI (p = 1). Tumor
extent measured with both radiopharmaceuticals correlated strongly with pathologic size (99mTc sestamibi, r = 0.84;
99mTc maraciclatide, r = 0.81). The L/B ratio in detected breast cancers was similar for the two radiopharmaceuticals: 1.
55 ± 0.36 (mean ± S.D.) for 99mTc sestamibi and 1.62 ± 0.37 (mean ± S.D.) for 99mTc maraciclatide (p = 0.53). No
correlation was found between the L/B ratio and molecular subtype for 99mTc sestamibi (rs = 0.12, p = 0.63) or
99mTc
maraciclatide (rs = −0.12, p = 0.64). Of 20 benign lesions, 10 (50%) were seen on
99mTc sestamibi and 9 of 20 (45%) were
seen on 99mTc maraciclatide images (p = 0.1). The average L/B ratio for benign lesions was 1.34 ±0.40 (mean ±S.D.) for
99mTc sestamibi and 1.41 ±0.52 (mean ±S.D.) for 99mTc maraciclatide (p = 0.75). Overall diagnostic performance was
similar for both radiopharmaceuticals. AUC from ROC analysis was 0.83 for 99mTc sestamibi and 0.87 for 99mTc
maraciclatide (p = 0.64).
Conclusions: 99mTc maraciclatide offered comparable lesion uptake to 99mTc sestamibi, in both malignant and benign
lesions. There was good correlation between lesion extent and uptake measured from both radiopharmaceuticals. 99mTc
maraciclatide offered a marginal (but not significant) improvement in sensitivity over 99mTc sestamibi. Our findings did
not support an association between the uptake of either radiopharmaceutical and tumor molecular subtype.
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Background
Molecular breast imaging (MBI) is a nuclear medicine
technique that utilizes a specialized gamma camera system
optimized for breast imaging. Because MBI relies on the
preferential uptake of a radiopharmaceutical in metabolic-
ally active cells to distinguish breast abnormalities from
normal parenchyma, the sensitivity of this technique is
not affected by mammographic breast density and has
been shown to improve detection of mammographically
occult cancers. In recent studies, supplemental screening
with MBI has been shown to detect an additional 7.5 to
16.5 cancers per 1000 women screened [1].
To date, most studies of MBI have utilized the radio-
pharmaceutical 99mTc sestamibi, with only limited re-
ports on the use of alternative radiopharmaceuticals for
breast imaging [2–6]. Tc-99m sestamibi is primarily used
as a perfusion agent for cardiac imaging, and was seren-
dipitously discovered to also accumulate in breast can-
cer. The biodistribution of Tc-99m sestamibi is such that
the relative uptake of Tc-99m sestamibi in breast cells is
a factor of 20 lower than in myocardial cells [7], and
hence only a small proportion of administered activity is
sequestered in breast tissue. Despite this low uptake,
MBI with Tc-99m sestamibi has been shown to be highly
sensitive for the detection of breast cancers [1]. However
some tumors are not well-visualized on MBI. In a series
of 286 patients with 390 tumor foci, 49 (12%) were oc-
cult on MBI; most of the lesions that were occult on
MBI with Tc-99m sestamibi were either small (5 mm or
less) and potentially below the resolving power of the
camera system or located outside the field of view; how-
ever, in 17 of 49 (35%), the reason for the absence of Tc-
99m sestamibi uptake in the lesion was unknown [8].
An ideal alternative radiopharmaceutical to Tc-99m
sestamibi would have a more favorable biodistribution to
breast tissue and offer better visualization of breast tu-
mors through higher uptake in breast malignancies rela-
tive to the amount of uptake in normal breast tissue. A
radiopharmaceutical of particular interest is the imaging
agent 99mTc-NC100692 (also known as Maraciclatide,
GE Healthcare), which is a synthetic cyclic peptide with
high affinity for specific integrins, such as αvβ3, that are
upregulated during angiogenesis [9]. Angiogenesis is
critical for the growth of solid tumors as tumor growth
beyond a volume of 1–2 mm3 requires independent vas-
culature [10, 11]. An indirect approach to imaging
angiogenesis has focused on radiotracers targeting the
integrin αvβ3 receptors which are significantly upregu-
lated in endothelial cells during angiogenesis and are
known to be expressed in breast cancer [12].
The αvβ3 integrin is a membrane-spanning protein
that is expressed preferentially on proliferating endothe-
lial cells associated with neovascularization but is absent
in quiescent blood vessels [13, 14]. The binding of 99mTc
maraciclatide has been confirmed to be localized to
endothelial cells in the regions of angiogenesis [15], and
may provide a promising alternative radiopharmaceutical
to 99mTc sestamibi. Bach-Gansmo et al. first reported on
the use of a 99mTc-labeled angiogenesis agent (99mTc
NC100692) for the detection of breast cancers using
MBI [16, 17].
The purpose of this study was to compare relative per-
formance of 99mTc sestamibi and 99mTc maraciclatide in
patients with suspected breast cancer, using a high-
resolution dedicated gamma camera for MBI.
Methods
Study population
This study was performed under an IRB-approved, Health
Insurance Portability and Accountability Act-compliant
research protocol, and written informed consent was ob-
tained from all participants. As 99mTc maraciclatide is a
not an FDA-approved radiopharmaceutical, this study was
performed under an investigator IND cross-referred to
the IND held by the radiopharmaceutical manufacturer,
GE Healthcare Life Sciences (Pittsburgh, PA).
Female patients with known or suspected breast cancer
were offered participation in the study. Eligible patients in-
cluded those with at least one breast lesion identified by
clinical findings, mammography, targeted ultrasound, or
magnetic resonance imaging that was considered suspi-
cious or highly suggestive of malignancy on the American
College of Radiology Breast Imaging Reporting and Data
System (BI-RADS) scale [18] and scheduled for biopsy.
MBI examinations were performed prior to breast biopsy
when possible (N = 32). Patients were also eligible to have
MBI performed after breast biopsy if the lesion was patho-
logically proven as malignant and estimated to be at least
1.5 cm in maximum diameter (N = 7). This requirement
on lesion size was to avoid recruitment of patients in
whom a significant portion of the lesion would likely be
removed at the time of biopsy.
Molecular breast imaging examinations
Patients underwent two MBI examinations—one with
99mTc sestamibi and one with 99mTc maraciclatide. MBI
was performed on a dual-head system that comprised
two compact cadmium zinc telluride detectors with
1.6 × 1.6 mm pixels (LumaGem system, Gamma Medica,
Salem, NH) and was equipped with high sensitivity reg-
istered tungsten collimators [19]. An energy acceptance
window of 110–154 keV was used [20, 21].
When possible, patients were scheduled for 99mTc ses-
tamibi and 99mTc maraciclatide MBI examinations on
separate days (2-day protocol; N = 20). If the patient
schedule did not permit a 2-day protocol, then a 1-day
protocol was followed (N = 19), as described below. For
logistical reasons related to preparation and quality
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control of the 99mTc maraciclatide and to the wait time
after injection of the 99mTc maraciclatide, the order of
the tests was not randomized. For all patients, MBI with
99mTc sestamibi was performed first, followed by MBI
with 99mTc maraciclatide. Between 24–72 h after injec-
tion of the 99mTc maraciclatide, patients were contacted
to determine if any adverse events (AEs) occurred.
2-day protocol
Patients received an intravenous injection of 300 MBq
(8 mCi) 99mTc sestamibi for the first MBI scan on day 1
and 300 MBq (8 mCi) 99mTc maraciclatide for the sec-
ond MBI scan on day 2, performed at least 16 h after
the day 1 examination. Injections were given in the
contralateral arm to the breast with the suspected lesion
and residual syringe activity was measured after injec-
tion. The times at which the injections were performed,
imaging was commenced, and dose activities were mea-
sured, were recorded to permit accurate correction for
decay of the 99mTc and computation of administered ac-
tivities. Imaging commenced approximately 5 min post-
injection with 99mTc sestamibi and approximately
45 min post-injection with 99mTc maraciclatide. The dif-
ference in wait time before imaging with 99mTc sestamibi
and 99mTc maraciclatide was to allow for known differ-
ences in rate of uptake of these radiopharmaceuticals in
breast tumors [16]. Bilateral cranio-caudal (CC) and
medio-lateral oblique (MLO) analogous views were ob-
tained under light compression for 10 min per view for
a total imaging time of 40 min. The compressed breast
thickness for each view acquired during the 99mTc sesta-
mibi MBI examination was recorded and replicated at
the 99mTc maraciclatide MBI examination to assist with
consistent positioning of the breast between studies.
1-day protocol
The 1-day protocol procedure was similar to that described
above, except that after completion of the first MBI scan,
performed with 300-MBq (8 mCi) injection of 99mTc sesta-
mibi, patients were immediately injected with 740 MBq
(20 mCi) 99mTc maraciclatide for the second MBI scan. Ap-
proximately 45 min post-injection of the 99mTc maracicla-
tide, images were acquired as described above.
The rationale for the higher administered dose of
99mTc maraciclatide for the 1-day protocol was to
minimize the contribution of 99mTc sestamibi to the sec-
ond scan. The time interval from injection of the 99mTc
sestamibi to acquisition of the 99mTc maraciclatide im-
ages was approximately 90 min for each patient (45 min
99mTc sestamibi injection and imaging, 45 min wait after
injection of 99mTc maraciclatide) allowing for physical
decay of the 99mTc sestamibi to at least 250 MBq, and
physical decay of the 99mTc maraciclatide to 680 MBq.
No adjustment was made for any biological washout.
Therefore, the relative contribution of counts from the
99mTc maraciclatide and 99mTc sestamibi injections in
the second MBI scan was anticipated to be approxi-
mately 2.7:1 (~680 MBq 99mTc maraciclatide/~250 MBq
99mTc sestamibi).
Histopathology
Histopathologic classification was by the most severe of
findings from surgical excision or by core needle or
vacuum-assisted biopsy. Tumor size was obtained from the
maximum tumor extent reported on pathology. Molecular
subtype of malignant lesions was characterized as luminal
(ER+ and HER2−), HER2-enriched (HER2+/ER−/PR−), or
triple negative (ER−/PR−/HER2−).
Image analysis
Image manipulation and region of interest (ROI) ana-
lysis were performed on the 99mTc maraciclatide and
99mTc sestamibi MBI images using an Xeleris workstation
(GE Healthcare, Milwaukee, WI).
Radiopharmaceutical uptake in breast lesions was
measured as a lesion-to-background (L/B) ratio, per-
formed as follows. A 3 × 3 median filter was first applied
to all images to minimize noise. An ROI was manually
drawn to encompass the area of focal uptake corre-
sponding to the lesion using the upper or lower detector
CC or MLO view that best visualized the lesion. This le-
sion ROI was copied to the complementary upper or
lower detector image. The maximum count in each le-
sion ROI was obtained and a geometric mean (GM) of
the two counts was calculated. Background activity was
measured from a second circumferential ROI that was
drawn over a region of normal tissue surrounding the le-
sion. This background ROI was again copied to the cor-
responding area of normal tissue on the upper or lower
detector image. The average count in each background
ROI was obtained and a geometric mean value was cal-
culated. L/B ratio was defined as
L=B ratio ¼ GM maximum counts in lesionð Þ =
GM average counts in backgroundð Þ
For the 1-day protocol studies, a cross-talk correction
was applied as follows. Count measurements from the
lesion and background ROIs from the 99mTc sestamibi
images were decay corrected for the time interval
between the 99mTc maraciclatide and 99mTc sestamibi
acquisitions and reduced further by a factor of 0.94 (to
adjust for biological washout of the 99mTc sestamibi
from breast tissue) [22]. These counts were then sub-
tracted from counts in the 99mTc maraciclatide images.
No cross-talk correction was necessary for the 2-day
protocol.
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MBI interpretation
A breast imaging fellowship-trained radiologist with
4 years of experience interpreting MBI (KNH) per-
formed two independent reading sessions, separated
by 4 weeks, of the MBI studies. Each session com-
prised a random order of 99mTc sestamibi and 99mTc
maraciclatide studies; only one study appeared for
each patient per session. The radiologist was blinded
to the radiopharmaceutical, other imaging findings,
and all clinical information including pathology find-
ings. MBI studies were interpreted according to a
validated lexicon for gamma imaging of the breast
[23, 24].
The radiologist identified breast lesions and assigned a
final assessment on a per-breast basis using a 1 to 5
scale that parallels BI-RADS assessment categories. As-
sessments were as follows: 1 (negative), 2 (benign), 3
(probably benign), and 4 (suspicious) or 5 (highly sug-
gestive of malignancy) [23]. Assessments of 3 or higher
were considered positive. Lesion size was measured from
the CC or MLO views that best demonstrated the full
extent of disease. The radiologist also gave an overall
assessment of image quality on a 4-category scale (poor,
suboptimal, acceptable, good).
Statistical analysis
The proportions of malignant tumors and benign lesions
detected by 99mTc maraciclatide and 99mTc sestamibi
were compared using McNemar’s test for correlated pro-
portions. A Wilcoxon signed-rank test was used to de-
termine whether assessment scores differed between the
99mTc maraciclatide and 99mTc sestamibi studies.
Tumor extent measured on 99mTc maraciclatide and
99mTc sestamibi imaging was compared using a paired t
test. The correlations between tumor extent measured
on imaging and lesion extent measured at pathology
were determined by Pearson correlation coefficient (r).
L/B ratios of lesions detected on 99mTc maraciclatide
and 99mTc sestamibi imaging were compared using
paired t-tests. A student’s t-test was used to compare L/
B ratio between malignant and benign lesions for each
radiopharmaceutical. Correlation in L/B ratio measured
on 99mTc maraciclatide and 99mTc sestamibi MBI were
also determined by Pearson correlation coefficient (r).
Area under the curve (AUC), obtained from ROC ana-
lysis of both radiopharmaceuticals, was used to deter-
mine the value of the L/B ratio in discriminating
between malignant and benign lesions. Correlation of L/
B ratios with tumor subtype, considered as three ordinal
categories (luminal, HER-2 enriched, triple negative),
was determined by Spearman correlation coefficient (rs).
Statistical analyses were two sided with a significance
level of 0.05.
Results
A total of 40 patients were enrolled in this study. One
patient withdrew after the initial MBI scan; thus, 39 pa-
tients successfully completed both MBI studies. In the
analyzable 39 patients, average age was 56.5 years (SD
12.3, range 41–82). There were no reported adverse
reactions.
Image quality was rated as good in all 39 99mTc
maraciclatide studies. In the 39 99mTc sestamibi stud-
ies, 32 (82%) were rated as having good image quality
and 7 (18%) were ranked as having acceptable image
quality. Review of the lesion and background counts
recorded from the images in patients who underwent
the 1-day protocol, showed a 99mTc maraciclatide/
99mTc sestamibi ratio of 2.4:1 in lesions and 2.3:1 in
background. These ratios are slightly lower than the
anticipated ratio of 2.7:1.
Malignant lesions
A total of 21 patients had a diagnosis of breast cancer
with a total of 21 malignant lesions identified (Table 1).
Eighteen of 21 tumors (86%) were seen on 99mTc sesta-
mibi MBI and 19 of 21 (90%) were seen on 99mTc mara-
ciclatide MBI (p = 1). Eighteen tumors were seen with
both radiopharmaceuticals, 1 was seen only on 99mTc
maraciclatide MBI, and 2 were not detected by MBI with
either radiopharmaceutical. The tumor detected only by
99mTc maraciclatide was an invasive lobular carcinoma
that was 2.5 cm on pathology but had an apparent ex-
tent of 9.3 cm on maraciclatide MBI (Table 1, tumor
#21; Fig. 1). The two malignant tumors not seen with ei-
ther radiotracer included a 6-mm and a 7-mm invasive
ductal carcinoma (Table 1, tumors #2 and #3).
The overall distribution of assessment scores differed
between 99mTc sestamibi and 99mTc maraciclatide
(Fig. 2a; p < 0.001). However, this difference appears to
be primarily due to the higher number of benign assess-
ments (category 2) seen with 99mTc maraciclatide relative
to 99mTc sestamibi and the corresponding lower number
of negative assessments (category 1) seen with 99mTc
maraciclatide, as no difference was observed in assess-
ment scores in the subset of patients with breast cancer
(Fig. 2b; p =N.S.).
Average tumor size on pathology was 3.5 cm (SD
3.3 cm; range 0.6 to 13.1 cm). Tumor extent measured
on MBI was similar for the two radiopharmaceuticals;
average tumor size was 4.3 cm (SD 3.6 cm) on the 99mTc
sestamibi images and 4.3 cm (SD 3.5 cm) on the 99mTc
maraciclatide images (p = 0.62). Tumor extent measure-
ments strongly correlated with pathology size (r = 0.82
for 99mTc sestamibi and r = 0.74 for 99mTc maraciclatide;
Fig. 3a, b). Figure 3c shows the correlation between
tumor extent measured from the 99mTc sestamibi and
99mTc maraciclatide images (r = 0.93). In one patient
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who underwent neoadjuvant chemotherapy (Fig. 4), no
pathologic estimate of tumor size was available. Tumor
extent from contrast-enhanced breast MRI performed
prior to chemotherapy was used as a reference standard
in this case.
Benign lesions
Benign biopsy findings were found in 20 patients
(Table 2). Nine of 20 (45%) benign lesions were seen on
99mTc sestamibi MBI and on 99mTc maraciclatide MBI.
Eight benign lesions were seen with both radiopharma-
ceuticals, 1 atypical ductal hyperplasia was seen only
with 99mTc maraciclatide, and 1 intramammary lymph
node was seen only with 99mTc sestamibi. Ten were not
detected by MBI with either radiopharmaceutical. Fig-
ure 5 shows an example of the relative findings on MBI
with both 99mTc sestamibi and 99mTc maraciclatide in a
patient with necrotizing granulomatous inflammation.
L/B ratio
The L/B ratio in detected breast cancers was similar for
the two radiopharmaceuticals: 1.55 ± 0.36 (mean ± SD)
for 99mTc sestamibi and 1.62 ± 0.37 (mean ± SD) for
99mTc maraciclatide (p = 0.53) and strongly correlated
(Fig. 6a; r = 0.82). The average L/B ratio for benign le-
sions was also similar for the two radiopharmaceuticals:
1.34 (SD 0.4) for 99mTc sestamibi and 1.41 (S.D. 0.52) for
99mTc maraciclatide (p = 0.75). The average L/B ratio for
malignant lesions was higher than that for benign lesions
for both 99mTc sestamibi, (1.55 vs 1.34, p = 0.18.) and
99mTc maraciclatide (1.62 vs. 1.41, p = 0.23), but the dif-
ference did not reach significance.




















1 DCIS 7.0 Not
applicable
4 4 10.3 8.3 1.54 1.79
2 IDC 0.6 Luminal 1 1 N/A N/A N/A N/A
3 IDC 0.7 Luminal 1 2 N/A N/A 1.02 1.15
4 IDC 0.8 Triple
negative
3 4 1.2 1.1 1.16 1.15
5 IDC 0.9 Luminal 4 4 1.1 1.3 1.29 1.37
6 IDC 1.2 Luminal 4 4 3.1 3.1 1.59 1.71
7 IDC 1.5 HER-2
positive
4 5 1.5 1.3 1.62 1.60
8 IDC 1.6 HER-2
positive
5 4 2.1 1.7 1.93 2.70
9 IDC 1.7 Luminal 4 4 1.0 1.8 1.12 1.11
10 IDC 1.8 Triple
negative
4 5 1.7 1.3 1.71 1.67
11 IDC 2.6 HER-2
positive
4 4 3.0 3.0 2.02 1.62
12 IDC 3.5 HER-2
positive
4 4 7.0 7.5 1.27 1.30
13 IDC 5.2 Luminal 4 4 3.0 3.3 1.57 1.50
14 IDC 5.4 Luminal 4 4 5.9 2.7 1.31 1.61
15 IDC 7.0 Luminal 5 4 3.0 3.0 1.63 1.79
16 IDC 9.2 Triple
negative
4 4 11.0 9.2 1.43 1.42
17 Mixed IDC/ILC 1.1 Luminal 4 4 1.0 1.1 1.41 1.55
18 Mixed IDC/ILC 1.6 Luminal 4 4 6.5 6.3 1.68 1.68
19 Mixed IDC/ILC 3.7 Luminal 4 4 2.8 5.4 2.17 2.07
20 Mixed IDC/ILC 13.1 Luminal 5 5 11.4 12.5 2.31 2.09
21 ILC 2.5 Luminal 1 4 N/A 9.3 1.15 1.49
DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma in situ
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Fig. 1 Molecular breast images in the mediolateral oblique projection from a 73-year-old patient with biopsy-proven invasive lobular carcinoma
(Table 1, tumor #21). At blinded review, MBI performed with 300 MBq 99mTc sestamibi (a) was interpreted as negative; MBI performed 3 days later
with 300 MBq 99mTc maraciclatide (b) was interpreted as assessment category 4. The lesion extent was 9.3 cm (arrows). Final pathology revealed
grade I invasive lobular carcinoma of luminal A subtype, forming a 2.5-cm mass
Fig. 2 Distribution of assessment scores in a all 78 breasts and b 21 breasts with proven breast cancer
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Figure 6b illustrates the correlation between lesion up-
take (both malignant and benign) for 99mTc sestamibi
and 99mTc maraciclatide as a function of the acquisition
protocol. No apparent bias in terms of L/B ratio as a
function of the type of protocol used to acquire the
studies was observed.
Figure 7 shows the results of the ROC analysis for
99mTc sestamibi and 99mTc maraciclatide. The overall
diagnostic performance did not differ between the
two radiopharmaceuticals. The AUC was 0.83 for
99mTc sestamibi and 0.87 for 99mTc maraciclatide (p =
0.64). A cut-off value of L/B = 1.2 yielded a sensitivity
Fig. 3 a Correlation between largest tumor extent recorded from pathology and largest tumor extent measured from 99mTc sestamibi images in
18 malignant tumors seen on MBI (r = 0.82). Open square = neoadjuvant chemotherapy, size estimated from MRI. b Correlation between largest
tumor extent recorded from pathology and largest tumor extent measured from 99mTc maraciclatide images in 19 malignant tumors seen on MBI
(r = 0.74). Open square = neoadjuvant chemotherapy, size estimated from MRI. c Correlation between tumor extent measured from 99mTc
sestamibi images and from 99mTc maraciclatide images in 18 malignant tumors detected on both scans (r = 0.93)
Fig. 4 Molecular breast images in the mediolateral oblique projection from a 53-year-old patient with a palpable lesion that was suspicious on
diagnostic mammography and scheduled for biopsy (Table 1, tumor #16). At blinded review, MBI performed with 300 MBq 99mTc sestamibi (a) was
interpreted as having moderate intensity radiotracer uptake in a segmental distribution with maximum extent of 11.0 cm. An assessment of 4 was
assigned. MBI performed 1 day later with 300 MBq 99mTc maraciclatide (b) was also interpreted as assessment 4 with lesion extent measuring 9.2 cm.
Pathology revealed grade III invasive ductal carcinoma. Patient underwent subsequent neoadjuvant chemotherapy. Tumor extent measured on
contrast-enhanced MRI prior to neoadjuvant chemotherapy was estimated at 9.2 cm
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Histopathology L/B ratio Assessment
99mTc sestamibi 99mTc maraciclatide 99mTc sestamibi 99mTc maraciclatide
1 ADH 1.24 1.28 3 3
2 ADHa Not seen 1.34 1 4
3 Benign fibrocystic changes Not seen Not seen 1 2
4 Benign fibrocystic changes Not seen Not seen 1 1
5 Benign fibrocystic changes Not seen Not seen 1 2
6 Benign fibrocystic changes Not seen Not seen 1 1
7 Benign fibrocystic changes Not seen Not seen 1 2
8 Benign fibrocystic changes Not seen Not seen 1 1
9 Fibroadenoma 1.52 1.35 3 3
10 Fibroadenoma Not seen Not seen 1 2
11 Fibroadenoma Not seen Not seen 1 1
12 Fibroadenoma Not seen Not seen 1 2
13 Fibroadenoma 1.24 1.13 3 4
14 Fibroadenoma 1.14 1.25 2 3
15 Fibroadenomab 1.12 1.11 4 4
16 Inflammatory tissue 1.25 1.36 4 4
17 Intramammary lymph node 1.14 Not seen 4 2
18 Papilloma Not seen Not seen 2 2
19 Papilloma 1.07 1.13 2 2
20 PASH 2.35 2.76 2 2
ADH atypical ductal hyperplasia, PASH pseudoangiomatous stromal hyperplasia
aPatient with invasive ductal carcinoma had ADH diagnosed in the contralateral breast
bPatient with invasive ductal carcinoma had a fibroadenoma in the ipsilateral breast
Fig. 5 Molecular breast images in the mediolateral oblique projection from a 41-year-old patient with a palpable lesion that was suspicious on
diagnostic mammography and scheduled for biopsy (Table 2, benign lesion #16). At blinded review, MBI performed with 300 MBq 99mTc sestamibi
(a) was interpreted as having a focal area of moderate intensity radiotracer uptake with maximum extent of 1.3 cm. An assessment of 4 was
assigned. MBI performed the same day with 740 MBq 99mTc maraciclatide (b) was also interpreted as assessment 4 with lesion extent measuring
1.6 cm. Biopsy revealed necrotizing granulomatous inflammation and fibrosis
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of 76% and a specificity of 75% for 99mTc sestamibi
and a sensitivity of 81% and a specificity of 70% for
99mTc maraciclatide.
Figure 8 shows the distribution of the lesion to
background (L/B) ratios measured from the 99mTc
sestamibi and 99mTc maraciclatide images as a func-
tion of molecular subtype. No correlation was found
between the L/B ratio and molecular subtype for
99mTc sestamibi (rs = 0.12, p = 0.63) or
99mTc maraci-
clatide (rs = −0.12, p = 0.64).
Discussion
The overall results of this study show that 99mTc maraci-
clatide offers comparable uptake in breast tumors to
99mTc sestamibi. Lesion extent and L/B ratio measured
from the 99mTc maraciclatide images correlated closely
with values measured from the 99mTc sestamibi images.
Our findings suggest that 99mTc maraciclatide offers only
a marginal improvement in sensitivity over 99mTc sesta-
mibi that did not reach significance in this study.
Both radiopharmaceuticals demonstrated comparable
uptake in benign lesions. It was hoped that the degree of
uptake of the 99mTc maraciclatide in these lesions would
be less than that of 99mTc sestamibi, thereby providing
better discrimination between benign and malignant le-
sions. However, factors that contribute to the uptake of
99mTc sestamibi in some benign lesions appear to equally
influence the uptake of 99mTc maraciclatide. Previous
studies have shown that angiogenesis in breast tissue is
initiated at the start of hyperplasia before there is any
morphological evidence of malignancy [25]. Hence, it is
not unexpected that there would be uptake of 99mTc
maraciclatide in benign lesions. The uptake is similar to
that observed with 99mTc sestamibi, thereby offering lit-
tle or no improvement in discriminating power between
benign and malignant lesions. ROC analysis (Fig. 7)
showed only a marginal, and non-significant, difference
Fig. 6 a Correlation between L/B ratio measured on malignant and benign lesions from 99mTc sestamibi and 99mTc maraciclatide images
(malignant, r = 0.82; benign, r = 0.96; all lesions, r = 0.87). b Correlation between L/B ratio in malignant and benign lesions from 99mTc sestamibi
and 99mTc maraciclatide images measured using the 1-day and 2-day protocols (1-day protocol, r = 0.89, solid line; 2-day protocol, r = 0.85,
dotted line)
Fig. 7 ROC analysis of L/B ratio comparing the sensitivity and
specificity of 99mTc sestamibi and 99mTc maraciclatide images. The
AUC was 0.83 and 0.87 for 99mTc sestamibi and 99mTc maraciclatide
respectively (p = 0.64)
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in the ability of the two radiopharmaceuticals to distin-
guish benign from malignant lesions.
Bach-Gansmo et al. [15, 16] were the first to report on
the high sensitivity of 99mTc maraciclatide for the detec-
tion of breast cancer. In their studies, no comparison of
the relative uptake of 99mTc maraciclatide with 99mTc
sestamibi was performed. Ma et al showed that an ana-
log of maraciclatide, 99mTc RGD, demonstrated margin-
ally better uptake in breast cancers than 99mTc sestamibi,
but that difference was not statistically significant. Fur-
thermore they found that 99mTc RGD did not provide
any significant advantage over 99mTc sestamibi in distin-
guishing benign from malignant lesions [6]. In agree-
ment with the findings of Ma et al, we found a good
correlation between the uptakes of the 2 radiopharma-
ceuticals and no difference in the ability of either radio-
pharmaceutical to distinguish malignant from benign
lesions (Fig. 7). Likewise, apparent lesion extent ap-
peared to be similar with both radiopharmaceuticals.
99mTc sestamibi is currently the only radiopharmaceu-
tical that is FDA-approved for breast imaging [26]. Sev-
eral recent studies have shown its clinical use as an
imaging agent for the detection of breast cancer in the
screening environment [27–29]. 99mTc sestamibi also of-
fers a practical advantage over 99mTc maraciclatide in
that it does not require a 45-min wait period post injec-
tion. With an excellent safety record and no serious ad-
verse events associated with over 30 years of clinical use
[30], 99mTc sestamibi has essentially become the primary
radiotracer used in the majority of MBI studies. Uptake
of 99mTc sestamibi in tumors is primarily dependent on
blood flow to the tumor bed and on increased uptake in
the mitochondria of the tumor cells [31]. As such, it has
served as a general-purpose imaging agent for the detec-
tion of breast cancer, but these same characteristics also
result in uptake in benign lesions and conditions such as
fibroadenomata, papillomas, areas of inflammation, ne-
crosis, and benign fibrocystic changes [32, 33].
99mTc maraciclatide may offer some advantages over
99mTc sestamibi for breast imaging. 99mTc sestamibi is
known to have significantly lower uptake in invasive
lobular carcinomas than in invasive ductal carcinomas
[8]. Figure 1 would indicate that 99mTc maraciclatide
may be a better imaging agent than 99mTc sestamibi for
the detection of invasive lobular carcinomas. However,
the same figure shows that 99mTc maraciclatide can oc-
casionally overestimate disease. The reason for this over-
estimation is unknown but may reflect hyperplasia in
the breast tissue surrounding the lesion. 99mTc maraci-
clatide is extracted primarily through the hepatobiliary
system with no uptake in the myocardium. In some pa-
tients, this may result in better breast image quality as
the absence of myocardial activity adjacent to the breast
may result in less scatter in the breast images. This point
is well demonstrated in Fig. 5 where increased activity
close to the chest wall is evident on the 99mTc sestamibi
image but absent from the 99mTc maraciclatide image.
Both radiopharmaceuticals have a comparable radiation
Fig. 8 Distribution of L/B ratios by molecular subtype in the 20 known invasive cancers for 99mTc sestamibi (rs = 0.12, p = 0.63) and
99mTc
maraciclatide (rs = −0.12, p = 0.64)
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dosimetry profile. The effective radiation dose from
99mTc maraciclatide is 7.8 uSv/MBq [34] which is com-
parable to that from 99mTc sestamibi (7.1 uSv/MBq)
[35]. However, no efforts have been expended to deter-
mine if the uptake of 99mTc maraciclatide in breast tissue
could be modulated through patient preparation as has
been done with 99mTc sestamibi [22].
One potential role for breast imaging with MBI is in
patients undergoing neoadjuvant chemotherapy (NAC)
where early prediction of response to NAC offers a po-
tential opportunity to change treatment strategy in cases
of inadequate response. Previous studies have shown
that quantitative assessment of tumor uptake of 99mTc
sestamibi demonstrated the ability to differentiate be-
tween pathological responders and non-responders as
early as 3–5 weeks after initiation of NAC [36]. To date,
there is little understanding of what these changes in
tumor uptake represent. Our findings did not support
an association between the uptake of either radiophar-
maceutical and molecular subtype. While the Luminal
cancers had some of the lowest L/B ratios, there was no
clear relationship between uptake and molecular sub-
type. Additional studies will be needed to determine
what relationship, if any, exists between the degree of
uptake of either radiopharmaceutical in a tumor and
molecular subtype or tumor histopathology.
This study had some limitations. The sample size of 40
patients limits our ability to detect small differences in the
sensitivity of the two radiopharmaceuticals. A second limi-
tation was the use of a 1-day protocol in approximately
half of patients, imposed by limitations in patient’s avail-
ability and inability to return for a 2-day protocol. Fig-
ure 6b showed no evidence that L/B ratios measured
using the 1-day protocol were biased high or low relative
to L/B ratios measured using the 2-day protocol. However,
in those patients who underwent the 1-day protocol,
image quality with the 99mTc maraciclatide images may
have been better than that observed in the 99mTc sestamibi
images due to the increased administered dose and corre-
sponding reduced noise in the clinical images. All of the
MBI examinations acquired for this study were considered
to be of adequate image quality for diagnostic interpret-
ation and appropriate adjustments to image counts were
made for ROI analyses. The order of MBI examinations
with the two radiopharmaceuticals was not randomized
due to restrictions with preparation of the 99mTc ma-
raciclatide; however, MBI studies were reviewed in a
randomized order with the radiologist blinded to ra-
diopharmaceutical and all clinical information in order to
avoid biasing the interpretation.
Conclusions
99mTc maraciclatide was found to offer comparable le-
sion uptake to 99mTc sestamibi, in both malignant and
benign lesions. Lesion extent and uptake measured from
the 99mTc maraciclatide images correlated closely with
values measured from the 99mTc sestamibi images. Our
findings suggest that 99mTc maraciclatide offers only a
marginal improvement in sensitivity over 99mTc sesta-
mibi that did not reach significance. Our findings did
not support an association between the uptake of either
radiopharmaceutical and molecular subtype of tumors.
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